As of Mar 27
| +0.37 / +0.88%|
The 12 analysts offering 12-month price forecasts for Neurocrine Biosciences Inc have a median target of 63.50, with a high estimate of 100.00 and a low estimate of 58.00. The median estimate represents a +49.94% increase from the last price of 42.35.
The current consensus among 13 polled investment analysts is to Buy stock in Neurocrine Biosciences Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.